Optimization of Theophylline Tablet Formula Using CoProcessed Excipients of Lactose and Avicel

Tablet excipients in direct compression should have good flowability and compactibility. Improvement of excipients properties may be obtained by coprocessing. Co-processing is defined as combining two or more excipients by an appropriate process. Co-processed excipients of lactose and avicel, which...

Full description

Saved in:
Bibliographic Details
Main Authors: Hayatus Sa`adah (Author), Achmad Fudholi (Author)
Format: Book
Published: Universitas Gadjah Mada, 2011-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tablet excipients in direct compression should have good flowability and compactibility. Improvement of excipients properties may be obtained by coprocessing. Co-processing is defined as combining two or more excipients by an appropriate process. Co-processed excipients of lactose and avicel, which were fabricated by spray drying technique, would be used as filler-binder in theophylline tablet formulation. The co-processed excipients were evaluated for their physical properties, i.e; particle size distribution, average diameter, density, flowability, compactibility and water absorption. Simplex lattice design was used for optimizing flowability, compactibility and water absorption of coprocessed excipients. The results showed that proportion of lactose and avicel with optimum physical properties was determined by the ratio 1:1 with a response of flowability was 8.79 ± 0.02 seconds, compactibility was 5.61 ± 0.08 kg and water absorption was 61.30 ± 0.40 mg/min. Superimposed contour plot of theophylline tablet formulation using co-processed excipients as filler-binder by factorial design was determined by the optimum proportion of magnesium stearate and eksplotab (1:3.74) with the response of hardness was 5.54 ± 0.042 kg, friability was 0.303 ± 0.015%, disintegration time was 1.83 ± 0.115 minutes and DE20was 85.66 ± 0.35%.
Item Description:http://dx.doi.org/10.14499/indonesianjpharm0iss0pp306-314
2338-9427
2338-9486